However, studies suggest that CAR patients who are seropositive for anti-recoverin antibodies may have improved survival compared to those who are seronegative [143, 144], possibly due to peripheral activation of recoverin-specific anti-tumor cytotoxic T-lymphocytes [143]. This evidence concerns the gene RCVRN and neoplasm.